EGFR is overexpressed in the majority of advanced epithelial ovarian carcinomas, and there is evidence indicating that overexpression is associated with poorer prognosis. In a phase III European Organisation for Research and Treatment of Cancer (EORTC)-Gynaecological Cancer Group and Gynecologic...
In a brief communication published in the Journal of the National Cancer Institute, Akbari et al reported finding a higher frequency of PPM1D mutations in circulating white blood cells from women with ovarian cancer vs controls, higher mortality associated with the mutation in women with ovarian...
In a study reported in The Lancet, Guglielmo Ronco, MD, of the Center for Cancer Epidemiology and Prevention, AO City of Health and Science, in Turin, Italy, and colleagues in the International HPV Screening Working Group performed a follow up of four randomized trials of human papillomavirus...
In a study reported in the Journal of Clinical Oncology, Patricia G. Moorman, PhD, of Duke University Medical Center, and colleagues evaluated risk of ovarian and breast cancer among oral contraceptive users with BRCA1/2 mutations. The study showed a significantly reduced risk of ovarian...
In a randomized phase II trial reported in the Journal of Clinical Oncology by R. Wendel Naumann, MD, of Carolinas Medical Center in Charlotte, North Carolina, and colleagues, the addition of vintafolide to pegylated liposomal doxorubicin improved progression-free survival in women with...
Pap cytology is more specific but less sensitive than human papillomavirus (HPV) testing for the detection of high-grade cervical intraepithelial neoplasia (CIN2+). In the pan-European PALMS study, reported in the Journal of the National Cancer Institute, Hans Ikenberg, MD, of CytoMol in...
Etirinotecan pegol is a topoisomerase-I inhibitor that prolongs systemic exposure to the active metabolite of irinotecan. In a phase II trial reported in Journal of Clinical Oncology, Ignace B. Vergote, MD, PhD, of University Hospital Leuven in Belgium, and colleagues found that the agent produced...
In a study reported in Journal of Clinical Oncology, Mathias Onrud, MD, of Norwegian Radium Hospital, Oslo University Hospital, and colleagues assessed outcomes in the follow-up of the Norwegian Radium Hospital trial to determine long-term effects of external beam radiation therapy in the adjuvant...
The primary analysis of the Japanese JGOG 3016 trial showed that dose-dense paclitaxel plus carboplatin significantly improved progression-free and overall survival compared with conventional paclitaxel/carboplatin as first-line treatment in patients with advanced ovarian cancer. In a long-term...
In a study reported in Journal of Clinical Oncology, Sebastien Gouy, MD, of Institut Gustave Roussy, and colleagues evaluated survival outcomes in locally advanced cervical cancer patients with negative PET-CT imaging results who underwent laparoscopic para-aortic staging surgery before...
Few markers of ovarian cancer prognosis have been established, perhaps because potential subtype associations are missed in studies including patients with all histopathologic subtypes. In a study reported in Lancet Oncology, Weiva Sieh, PhD, of Stanford University and colleagues assessed the...
Although patients with early-stage type I endometrial cancer have very good prognosis, a substantial proportion experience recurrence and die from the disease. In a study published in Journal of the National Cancer Institute, Alain G. Zeimet, MD, PhD, of Innsbruck Medical University, Austria, and...